Oct. 11 Quick Takes: European Parliament proposes amendments to pharma legislation
Plus: Early stop for Novo’s kidney outcomes study of semaglutide; Agomab raises $100M series B; and updates from MinervaX, FDA, ARPA-H, Tempest, Kanvas-Federation Bio
The European Parliament’s Committee on the Environment, Public Health and Food Safety has posted a draft report with amendments to a European Commission proposal for the first major overhaul of European pharmaceutical law in 20 years, and amendments to an associated directive. Debate on the amendments could start next week.
Shares of dialysis providers sank Wednesday after Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) said the Phase III FLOW kidney outcomes study of Ozempic semaglutide met criteria for an early stop due to efficacy. FLOW compared the once-weekly injectable drug with placebo in patients with Type II diabetes and chronic kidney disease. Novo gained 6% in New York, while shares of DaVita Inc. (NYSE:DVA) were off 17% and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) lost 18%...